The role of granulocyte colony-stimulating factors in the prevention of neutropenia and febrile neutropenia – the current state of knowledge Review article
Article Sidebar
Published:
Dec 14, 2016
Keywords:
neutropenia, neutropenic fever, long-and short-acting granulocyte colony-stimulating factors, guidelines, reveiw
Main Article Content
Abstract
Granulocyte colony-stimulating factors, introduced in the 1990s to prevent neutropenic fever, improve patients’ prognosis after myelotoxic chemotherapy. G-CSFs accelerate bone marrow recovery, shortening the duration of neutropenia and reducing its intensity as well as the risk of febrile neutropenia. There are short- and long-acting G-CSFs available these days. This paper is a review of the efficacy, toxicity and indications for short- and long-acting G-CSFs as indicated in the most recent studies.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Article Details
How to Cite
1.
Sobas MA, Wróbel T. The role of granulocyte colony-stimulating factors in the prevention of neutropenia and febrile neutropenia – the current state of knowledge. OncoReview [Internet]. 2016Dec.14 [cited 2024Nov.23];7(1(25):15-1. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/437
Issue
Section
HAEMATOLOGY IN ONCOLOGY
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Klastersky J, de Naurois J, Rolston K et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016; Suppl. 5: v111-v118.
2. Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47(1): 8-32.
3. NCCN Clinical Practice Guidelines in Oncology, Myeloid Growth Factors, Version 2.2016.
4. Smith TJ, Bohlke K, Lyman GH et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33(28): 3199-3212.
5. Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2013; 21(5): 1487-1495.
6. Pettengell R, Schwenkglenks M, Leonard R et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INCEU prospective observational European neutropenia study. Support Care Cancer 2008; 16(11): 1299-1309.
7. Bosly A, Bron D, Van Hoof A et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2008; 87(4): 277-283.
8. Kaushansky K. Lineage-specific hematopoietic growth factor. N Engl J Med 2006; 354(19): 2034-2045.
9. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325(3): 164-170.
10. Holmes FA, Jones SE, O’Shaughnessy J et al. Comparable efficacy and safety of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903-909.
11. Green M, Koelbl H, Baselga J et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
12. Mitchell A, Li X, Woods M et al. Comparative effectiveness of granulocyte colony-stimulation factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review. J Oncol Pharm Pract 2016; 22(5): 702-716.
13. Wang L, Baser O, Kutikova L et al. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 2015; 23(11): 3131-3140.
14. Mhaskar R, Clark OA, Lyman G et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 2014; (10): CD003039.
15. Kim MG, Han N, Lee E et al. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis. Bone Marrow Transplant 2015; 50(4): 523-530.
16. Gerds A, Fox-Geiman M, Dawravoo K et al. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2010; 16(5): 678-685.
17. Frączak E, Dybko J, Rybka J et al. The effect of lipegfilgrastim in hematopoietic reconstitution and supportive treatment after megachemotherapy with autologous peripheral blood stem cell transplantation in patients with lymphoproliferative malignancies. OncoReview 2016; 6(2): 66-71.
18. Link H, Nietsch J, Kerkmann M et al. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy – representative sample survey in Germany. Support Care Cancer 2016; 24(1): 367-376.
19. Lugtenburg P, Silvestre AS, Rossi FG et al. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Clin Lymphoma Myeloma Leuk 2012; 12(5): 297-305.
20. Cesaro S, Nesi F, Tridello G et al. A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant. PloS One 2012; 5: 713-720.
21. Lyman GH, Reiner M, Morrow PK et al. The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppresive chemotherapy. Ann Oncol 2015; 26(7): 1452-1458.
22. Drullinsky P, Sugarman SM, Fornier MN et al. Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. Clin Breast Cancer 2010; 10(6): 440-444.
23. Chatta GS, Price TH, Allen RC et al. Effects of in vivo recombinant methionyl human granulocyte colony stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994; 84(9): 2923-2929.
24. Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996; 88(1): 335-340.
25. Cooper KL, Madan J, Whyte S et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011; 11: 404.
26. Hershman DL, Wilde ET, Wright JD et al. Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol 2012; 30(8): 806-812.
27. Lyman GH, Dale DC, Wolff DA et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010; 28(17): 2914-2924.
2. Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47(1): 8-32.
3. NCCN Clinical Practice Guidelines in Oncology, Myeloid Growth Factors, Version 2.2016.
4. Smith TJ, Bohlke K, Lyman GH et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33(28): 3199-3212.
5. Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2013; 21(5): 1487-1495.
6. Pettengell R, Schwenkglenks M, Leonard R et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INCEU prospective observational European neutropenia study. Support Care Cancer 2008; 16(11): 1299-1309.
7. Bosly A, Bron D, Van Hoof A et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2008; 87(4): 277-283.
8. Kaushansky K. Lineage-specific hematopoietic growth factor. N Engl J Med 2006; 354(19): 2034-2045.
9. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325(3): 164-170.
10. Holmes FA, Jones SE, O’Shaughnessy J et al. Comparable efficacy and safety of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903-909.
11. Green M, Koelbl H, Baselga J et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
12. Mitchell A, Li X, Woods M et al. Comparative effectiveness of granulocyte colony-stimulation factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review. J Oncol Pharm Pract 2016; 22(5): 702-716.
13. Wang L, Baser O, Kutikova L et al. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 2015; 23(11): 3131-3140.
14. Mhaskar R, Clark OA, Lyman G et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 2014; (10): CD003039.
15. Kim MG, Han N, Lee E et al. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis. Bone Marrow Transplant 2015; 50(4): 523-530.
16. Gerds A, Fox-Geiman M, Dawravoo K et al. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2010; 16(5): 678-685.
17. Frączak E, Dybko J, Rybka J et al. The effect of lipegfilgrastim in hematopoietic reconstitution and supportive treatment after megachemotherapy with autologous peripheral blood stem cell transplantation in patients with lymphoproliferative malignancies. OncoReview 2016; 6(2): 66-71.
18. Link H, Nietsch J, Kerkmann M et al. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy – representative sample survey in Germany. Support Care Cancer 2016; 24(1): 367-376.
19. Lugtenburg P, Silvestre AS, Rossi FG et al. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Clin Lymphoma Myeloma Leuk 2012; 12(5): 297-305.
20. Cesaro S, Nesi F, Tridello G et al. A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant. PloS One 2012; 5: 713-720.
21. Lyman GH, Reiner M, Morrow PK et al. The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppresive chemotherapy. Ann Oncol 2015; 26(7): 1452-1458.
22. Drullinsky P, Sugarman SM, Fornier MN et al. Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. Clin Breast Cancer 2010; 10(6): 440-444.
23. Chatta GS, Price TH, Allen RC et al. Effects of in vivo recombinant methionyl human granulocyte colony stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994; 84(9): 2923-2929.
24. Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996; 88(1): 335-340.
25. Cooper KL, Madan J, Whyte S et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011; 11: 404.
26. Hershman DL, Wilde ET, Wright JD et al. Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol 2012; 30(8): 806-812.
27. Lyman GH, Dale DC, Wolff DA et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010; 28(17): 2914-2924.